Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis.

Saini NY, Ma J, Milton DR, Patel RD, Varma A, Bashir Q, Delgado RE, Tang G, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi A, Ahmed S, Mehta R, Srour S, Khouri IF, Iyer S, Weber D, Thomas SK, Lee HC, Manasanch EE, Patel K, Orlowski RZ, Champlin RE, Qazilbash MH.

Clin Cancer Res. 2019 Sep 3. pii: clincanres.0706.2019. doi: 10.1158/1078-0432.CCR-19-0706. [Epub ahead of print]

PMID:
31481508
2.

Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?

Yildiz P, Aung PP, Milton DR, Hruska C, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala C, Prieto VG.

Am J Dermatopathol. 2019 Aug 22. doi: 10.1097/DAD.0000000000001511. [Epub ahead of print]

PMID:
31464719
3.

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.

Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2019 Jul 8:1-8. doi: 10.1080/10428194.2019.1633633. [Epub ahead of print]

PMID:
31282244
4.

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.

Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP.

Cancers (Basel). 2019 May 29;11(6). pii: E754. doi: 10.3390/cancers11060754.

5.

Characterization of Viral Infections after Antithymocyte Globulin-Based Conditioning in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Figgins B, Hammerstrom A, Ariza-Heredia E, Oran B, Milton DR, Yeh J.

Biol Blood Marrow Transplant. 2019 May 22. pii: S1083-8791(19)30331-3. doi: 10.1016/j.bbmt.2019.05.020. [Epub ahead of print]

PMID:
31128324
6.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

PMID:
30910541
7.

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response.

Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT.

J Cutan Pathol. 2019 Sep;46(9):627-636. doi: 10.1111/cup.13454. Epub 2019 Apr 11.

PMID:
30883858
8.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1347-1354. doi: 10.1016/j.bbmt.2019.02.022. Epub 2019 Mar 1.

PMID:
30826465
9.

HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.

Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q.

Curr Res Transl Med. 2019 May;67(2):51-55. doi: 10.1016/j.retram.2019.01.001. Epub 2019 Jan 23.

PMID:
30683577
10.

Supplemental ultrasound screening in patients with a history of lobular neoplasia.

Phalak KA, Milton DR, Yang WT, Bevers TB, Dogan BE.

Breast J. 2019 Mar;25(2):250-256. doi: 10.1111/tbj.13191. Epub 2019 Jan 24.

PMID:
30675929
11.

The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.

Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA.

Clin Cancer Res. 2019 Mar 1;25(5):1650-1663. doi: 10.1158/1078-0432.CCR-18-1163. Epub 2018 Dec 11.

PMID:
30538110
12.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
13.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
14.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

15.

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.

Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO.

Bone Marrow Transplant. 2019 Jun;54(6):839-848. doi: 10.1038/s41409-018-0344-9. Epub 2018 Sep 26.

PMID:
30258129
16.

Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE.

Blood Adv. 2018 Sep 11;2(17):2254-2261. doi: 10.1182/bloodadvances.2018021899.

17.

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH.

Leuk Lymphoma. 2019 Feb;60(2):442-452. doi: 10.1080/10428194.2018.1485908. Epub 2018 Jul 22.

PMID:
30032678
18.

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA.

Curr Radiopharm. 2018;11(2):147-152. doi: 10.2174/1874471011666180629145030.

PMID:
29956640
19.

Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers.

Mauzo SH, Milton DR, Prieto VG, Torres-Cabala CA, Wang WL, Chakravarti N, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Brown RE, Aung PP.

Ann Diagn Pathol. 2018 Jun;34:151-154. doi: 10.1016/j.anndiagpath.2018.03.005. Epub 2018 Mar 15.

PMID:
29660567
20.

Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma.

Al-Rohil RN, Milton DR, Nagarajan P, Curry JL, Feldmeyer L, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

Hum Pathol. 2018 Jul;77:98-107. doi: 10.1016/j.humpath.2018.03.017. Epub 2018 Mar 28.

PMID:
29601841
22.

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.

Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, Vence LM, Allison JP, Gulbis AM, Sharma P.

Clin Cancer Res. 2018 Mar 1;24(5):1011-1018. doi: 10.1158/1078-0432.CCR-17-2777. Epub 2017 Dec 15.

23.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis.

Yeh JC, Shank BR, Milton DR, Qazilbash MH.

Biol Blood Marrow Transplant. 2018 Apr;24(4):815-819. doi: 10.1016/j.bbmt.2017.11.040. Epub 2017 Dec 6.

24.

Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.

Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO.

Biol Blood Marrow Transplant. 2018 Feb;24(2):353-358. doi: 10.1016/j.bbmt.2017.09.018. Epub 2017 Oct 3.

25.

Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.

Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA.

Ann Surg Oncol. 2017 Oct;24(10):2925-2934. doi: 10.1245/s10434-017-5958-4. Epub 2017 Aug 1.

26.

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q.

Cancer. 2017 Sep 15;123(18):3568-3575. doi: 10.1002/cncr.30770. Epub 2017 May 17.

27.

Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE.

Am J Hematol. 2017 Aug;92(8):E168-E171. doi: 10.1002/ajh.24776. Epub 2017 May 30. No abstract available.

28.

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO.

Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12. No abstract available.

29.

Prognostic Index for Critically Ill Allogeneic Transplantation Patients.

Bayraktar UD, Milton DR, Shpall EJ, Rondon G, Price KJ, Champlin RE, Nates JL.

Biol Blood Marrow Transplant. 2017 Jun;23(6):991-996. doi: 10.1016/j.bbmt.2017.03.003. Epub 2017 Mar 3.

30.

Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.

Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C.

Melanoma Res. 2017 Apr;27(2):126-133. doi: 10.1097/CMR.0000000000000329.

PMID:
28118269
31.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

32.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO.

Biol Blood Marrow Transplant. 2017 Feb;23(2):318-324. doi: 10.1016/j.bbmt.2016.11.008. Epub 2016 Nov 14.

33.

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.

Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q.

Cancer. 2016 Dec 15;122(24):3831-3837. doi: 10.1002/cncr.30366. Epub 2016 Sep 28.

34.

Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.

Siroy AE, Aung PP, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Milton DR, Curry JL, Ivan D, Prieto VG.

Hum Pathol. 2017 Jan;59:48-54. doi: 10.1016/j.humpath.2016.09.010. Epub 2016 Sep 22.

PMID:
27666765
35.

Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI.

J Clin Endocrinol Metab. 2016 Dec;101(12):4871-4877. Epub 2016 Sep 23.

36.

BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.

Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA, Curry JL.

Hum Pathol. 2016 Apr;50:79-89. doi: 10.1016/j.humpath.2015.12.003. Epub 2015 Dec 18.

PMID:
26997441
37.

Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.

Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN.

Am J Surg Pathol. 2016 May;40(5):676-88. doi: 10.1097/PAS.0000000000000614.

PMID:
26872013
38.

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.

Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE 3rd, Swanston NM, Fox P, Macapinlac HA, Rohren EM.

Clin Nucl Med. 2016 Apr;41(4):268-73. doi: 10.1097/RLU.0000000000001118.

PMID:
26828141
39.

Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.

Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2016 May;29(3):297-308. doi: 10.1111/pcmr.12455. Epub 2016 Mar 15.

40.

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL Jr, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA.

Clin Cancer Res. 2016 Jun 15;22(12):3016-24. doi: 10.1158/1078-0432.CCR-15-2226. Epub 2016 Jan 18.

41.

Assessing the role of ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis.

Etchebehere EC, Hobbs BP, Milton DR, Malawi O, Patel S, Benjamin RS, Macapinlac HA.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):860-70. doi: 10.1007/s00259-015-3242-z. Epub 2015 Dec 3. Review.

42.

Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.

Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO.

Biol Blood Marrow Transplant. 2016 Mar;22(3):505-13. doi: 10.1016/j.bbmt.2015.10.020. Epub 2015 Oct 31.

43.

Dual Roles of RNF2 in Melanoma Progression.

Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L.

Cancer Discov. 2015 Dec;5(12):1314-27. doi: 10.1158/2159-8290.CD-15-0493. Epub 2015 Oct 8.

44.

Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):8-20. doi: 10.1007/s00259-015-3185-4. Epub 2015 Sep 29.

PMID:
26416392
45.

Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation.

Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1392-8. doi: 10.1016/j.bbmt.2015.05.001. Epub 2015 May 15.

46.

Epithelial to mesenchymal transition is associated with rapamycin resistance.

Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F.

Oncotarget. 2015 Aug 14;6(23):19500-13.

47.

Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas.

Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH.

J Thorac Oncol. 2015 Mar;10(3):518-26. doi: 10.1097/JTO.0000000000000457.

48.

Inflammatory IL-1β-driven JNK activation in stage III melanoma.

Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2015 Mar;28(2):236-9. doi: 10.1111/pcmr.12348. Epub 2015 Jan 12. No abstract available.

PMID:
25546243
49.

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1975-81. doi: 10.1016/j.bbmt.2014.08.013. Epub 2014 Sep 28.

50.

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA.

J Invest Dermatol. 2015 Feb;135(2):508-515. doi: 10.1038/jid.2014.366. Epub 2014 Aug 22.

Supplemental Content

Loading ...
Support Center